Cogent Biosciences, Inc. Payments to Acquire Marketable Securities
Cogent Biosciences, Inc. (COGT) reported Payments to Acquire Marketable Securities of $216.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-10
- Cogent Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $82.81M, a 21.98% increase year-over-year.
- Cogent Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $133.84M.
- Cogent Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $395.22M, a 3006.11% increase year-over-year.
- Cogent Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $224.07M, a 1050.95% increase year-over-year.
- Cogent Biosciences, Inc. payments to acquire marketable securities for fiscal 2025 was $687.17M, a 168.84% increase from fiscal 2024.
- Cogent Biosciences, Inc. payments to acquire marketable securities for fiscal 2024 was $255.60M, a 26.72% decline from fiscal 2023.
- Cogent Biosciences, Inc. payments to acquire marketable securities for fiscal 2023 was $348.80M, a 96.12% increase from fiscal 2022.
- Cogent Biosciences, Inc. payments to acquire marketable securities for fiscal 2022 was $177.85M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $82.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $216.65M 10-Q · filed 2026-08-10 | $611.87M derived: sum of 3 quarters · filed 2026-08-10 | $835.93M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $133.84M 10-Q · filed 2026-05-05 | $529.06M derived: sum of 2 quarters · filed 2026-05-05 | $753.13M derived: sum of 3 quarters · filed 2026-05-05 | $821.01M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $395.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $619.29M derived: sum of 2 quarters · filed 2026-02-17 | $687.17M derived: sum of 3 quarters · filed 2026-08-10 | $687.17M 10-K · filed 2026-02-17 |
| 2025-09-30 | $224.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $291.95M derived: sum of 2 quarters · filed 2026-08-10 | $291.95M 10-Q · filed 2025-11-07 | $304.67M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $67.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $67.88M 10-Q · filed 2026-08-10 | $80.61M derived: sum of 3 quarters · filed 2026-08-10 | $100.08M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-05 | $12.72M derived: sum of 2 quarters · filed 2026-05-05 | $32.19M derived: sum of 3 quarters · filed 2026-05-05 | $182.59M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $12.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $32.19M derived: sum of 2 quarters · filed 2026-02-17 | $182.59M derived: sum of 3 quarters · filed 2026-02-17 | $255.60M 10-K · filed 2026-02-17 |
| 2024-09-30 | $19.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $169.87M derived: sum of 2 quarters · filed 2025-11-07 | $242.88M 10-Q · filed 2025-11-07 | $293.79M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $150.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $223.41M 10-Q · filed 2025-08-05 | $274.33M derived: sum of 3 quarters · filed 2026-02-17 | $386.80M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $73.01M 10-Q · filed 2025-05-06 | $123.93M derived: sum of 2 quarters · filed 2026-02-17 | $236.40M derived: sum of 3 quarters · filed 2026-02-17 | $362.80M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $50.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $163.39M derived: sum of 2 quarters · filed 2026-02-17 | $289.79M derived: sum of 3 quarters · filed 2026-02-17 | $348.80M 10-K · filed 2026-02-17 |
| 2023-09-30 | $112.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $238.88M derived: sum of 2 quarters · filed 2024-11-12 | $297.89M 10-Q · filed 2024-11-12 | $327.51M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $126.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $185.42M 10-Q · filed 2024-08-06 | $215.04M derived: sum of 3 quarters · filed 2025-02-25 | |
| 2023-03-31 | $59.01M 10-Q · filed 2024-05-07 | $88.64M derived: sum of 2 quarters · filed 2025-02-25 | ||
| 2022-12-31 | $29.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $177.85M 10-K · filed 2025-02-25 | ||
| 2022-09-30 | $148.23M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-26 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $0.00 derived: sum of 2 quarters · filed 2020-03-26 | $47.68M 10-K · filed 2020-03-26 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $47.68M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $47.68M 10-Q · filed 2019-08-12 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | $0.00 derived: sum of 2 quarters · filed 2019-03-28 | $2.00M derived: sum of 3 quarters · filed 2019-03-28 | $6.50M 10-K · filed 2019-03-28 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $2.00M derived: sum of 2 quarters · filed 2018-11-13 | $6.50M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $6.50M 10-Q · filed 2018-08-13 | ||
| 2017-03-31 | $4.50M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |